SW
BPMC

SVB Wealth’s Blueprint Medicines BPMC Stock Holding History

SVB Wealth’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77
Closed -$6.82K – 682
2025
Q1 		$6.82K Buy
+77
New +$7.51K ﹤0.01% 959
2023
Q1 		– Sell
-7,505
Closed -$329K – 1017
2022
Q4 		$329K Sell
7,505
-722
-9% -$34.6K ﹤0.01% 710
2022
Q3 		$542K Buy
8,227
+17
+0.2% +$1.09K 0.01% 508
2022
Q2 		$415K Hold
8,210
– – 0.01% 481
2022
Q1 		$525K Sell
8,210
-9
-0.1% -$646 0.01% 444
2021
Q4 		$880K Buy
8,219
+7
+0.1% +$732 0.01% 326
2021
Q3 		$844K Sell
8,212
-1,088
-12% -$101K 0.01% 439
2021
Q2 		$818K Buy
9,300
+711
+8% +$65.2K 0.01% 437
2021
Q1 		$835K Buy
8,589
+1,089
+15% +$109K 0.01% 391
2020
Q4 		$841K Hold
7,500
– – 0.01% 358
2020
Q3 		$695K Buy
+7,500
New +$578K 0.01% 351

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SVB Wealth's BPMC Position: Q2 2025 in Review

SVB Wealth sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 77 shares — an estimated $6.82K sold.

SVB Wealth first reported a position in BPMC in Q3 2020 and held it in 11 quarters. The position peaked at $880K in Q4 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • SVB Wealth reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • SVB Wealth sold 77 Blueprint Medicines shares in Q2 2025, an estimated $6.82K.
  • SVB Wealth first reported a position in Blueprint Medicines in Q3 2020 and held it in 11 quarters.
  • SVB Wealth's Blueprint Medicines position peaked at $880K in Q4 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.